BR0115621A - Sais de isotiazol-4-carboxamida e seus usos como agentes anti-hiperproliferação - Google Patents
Sais de isotiazol-4-carboxamida e seus usos como agentes anti-hiperproliferaçãoInfo
- Publication number
- BR0115621A BR0115621A BR0115621-7A BR0115621A BR0115621A BR 0115621 A BR0115621 A BR 0115621A BR 0115621 A BR0115621 A BR 0115621A BR 0115621 A BR0115621 A BR 0115621A
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- agents
- antihyperproliferation
- isothiazole
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"SAIS DE ISOTIAZOL-4-CARBOXAMIDA E SEUS USOS COMO AGENTES ANTI-HIPERPROLIFERAçãO". A invenção refere-se às formas de sal cloridrato, bromidrato, hemicitrato, acetato, p-tosilato, L-tartarato, hemissuccinato e mesilato da amida do ácido 3-(4-bromo-2,6-difluorobenzilóxi)-5-[3-(4-pirrolidin-1-il-butil)-ureído]-iso tiazol-4-carboxílico possuindo a fórmula: A invenção refere-se também a composições farmacêuticas contendo os sais cloridrato, bromidrato, hemicitrato, acetato, p-tosilato, L-tartarato, hemissuccinato e mesilato da fórmula I. A invenção refere-se ainda a métodos para tratar doenças hiperproliferativas, tais como cânceres, em mamíferos, especialmente seres humanos, pela administração dos sais anteriores e a métodos para preparar as formas cristalinas dos sais anteriores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25351300P | 2000-11-28 | 2000-11-28 | |
PCT/IB2001/002193 WO2002044158A1 (en) | 2000-11-28 | 2001-11-19 | Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0115621A true BR0115621A (pt) | 2003-09-02 |
Family
ID=22960587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0115621-7A BR0115621A (pt) | 2000-11-28 | 2001-11-19 | Sais de isotiazol-4-carboxamida e seus usos como agentes anti-hiperproliferação |
Country Status (50)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
BR0312798A (pt) * | 2002-07-25 | 2005-05-03 | Pfizer Prod Inc | Derivados de isotiazol úteis como agentes anticancerìgenos |
AP2005003232A0 (en) * | 2002-08-19 | 2005-03-31 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases. |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
RU2317295C1 (ru) * | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
TW200538104A (en) * | 2004-05-17 | 2005-12-01 | Pfizer Prod Inc | Phenyl derivatives for the treatment of abnormal cell growth |
EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
SI2044043T2 (sl) | 2006-06-16 | 2021-04-30 | H. Lundbeck A/S | 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje |
US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
BRPI0719883A2 (pt) | 2006-10-09 | 2015-05-05 | Takeda Pharmaceutical | Inibidores de quinase |
MX2010001636A (es) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
CA2806921C (en) | 2010-07-23 | 2019-11-26 | Trustees Of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
EP2968650B1 (en) * | 2013-03-14 | 2019-01-16 | PanOptica, Inc. | Ocular formulations for drug-delivery to the posterior segment of the eye |
EP3193867B1 (en) * | 2014-09-17 | 2021-01-20 | PanOptica, Inc. | Ocular formulations for drug-delivery and protection of the anterior segment of the eye |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
-
2001
- 2001-11-19 KR KR1020057022534A patent/KR20050116401A/ko active IP Right Grant
- 2001-11-19 ES ES01982663T patent/ES2271086T3/es not_active Expired - Lifetime
- 2001-11-19 JP JP2002546528A patent/JP2004514714A/ja not_active Withdrawn
- 2001-11-19 AU AU1420402A patent/AU1420402A/xx active Pending
- 2001-11-19 DK DK01982663T patent/DK1337521T3/da active
- 2001-11-19 HU HU0302553A patent/HUP0302553A3/hu unknown
- 2001-11-19 NZ NZ525788A patent/NZ525788A/en unknown
- 2001-11-19 CZ CZ20031315A patent/CZ20031315A3/cs unknown
- 2001-11-19 YU YU36403A patent/YU36403A/sh unknown
- 2001-11-19 OA OA1200300137A patent/OA12532A/en unknown
- 2001-11-19 IL IL15537101A patent/IL155371A0/xx unknown
- 2001-11-19 AT AT01982663T patent/ATE340786T1/de not_active IP Right Cessation
- 2001-11-19 AU AU2002214204A patent/AU2002214204B2/en not_active Ceased
- 2001-11-19 UA UA2003054858A patent/UA74221C2/uk unknown
- 2001-11-19 KR KR10-2003-7007057A patent/KR20030059275A/ko not_active Application Discontinuation
- 2001-11-19 WO PCT/IB2001/002193 patent/WO2002044158A1/en active IP Right Grant
- 2001-11-19 EE EEP200300247A patent/EE200300247A/xx unknown
- 2001-11-19 PT PT01982663T patent/PT1337521E/pt unknown
- 2001-11-19 CN CNB018193285A patent/CN1231474C/zh not_active Expired - Fee Related
- 2001-11-19 BR BR0115621-7A patent/BR0115621A/pt not_active Application Discontinuation
- 2001-11-19 SK SK586-2003A patent/SK5862003A3/sk unknown
- 2001-11-19 PL PL01362079A patent/PL362079A1/xx not_active Application Discontinuation
- 2001-11-19 MX MXPA03004714A patent/MXPA03004714A/es active IP Right Grant
- 2001-11-19 EP EP01982663A patent/EP1337521B1/en not_active Expired - Lifetime
- 2001-11-19 GE GE5216A patent/GEP20053652B/en unknown
- 2001-11-19 AP APAP/P/2001/002358A patent/AP2001002358A0/en unknown
- 2001-11-19 DE DE60123461T patent/DE60123461T2/de not_active Expired - Lifetime
- 2001-11-19 CA CA002430065A patent/CA2430065C/en not_active Expired - Lifetime
- 2001-11-19 EA EA200300424A patent/EA005859B1/ru not_active IP Right Cessation
- 2001-11-19 DO DO2001000288A patent/DOP2001000288A/es unknown
- 2001-11-19 SI SI200130630T patent/SI1337521T1/sl unknown
- 2001-11-26 MY MYPI20015382A patent/MY136686A/en unknown
- 2001-11-26 AR ARP010105484A patent/AR031512A1/es not_active Application Discontinuation
- 2001-11-26 UY UY27039A patent/UY27039A1/es not_active Application Discontinuation
- 2001-11-26 PE PE2001001179A patent/PE20020591A1/es not_active Application Discontinuation
- 2001-11-27 SV SV2001000748A patent/SV2002000748A/es unknown
- 2001-11-27 TN TNTNSN01167A patent/TNSN01167A1/fr unknown
- 2001-11-27 TW TW090129315A patent/TWI287542B/zh active
- 2001-11-27 PA PA20018533801A patent/PA8533801A1/es unknown
- 2001-11-27 GT GT200100237A patent/GT200100237A/es unknown
- 2001-11-27 HN HN2001000268A patent/HN2001000268A/es unknown
- 2001-11-27 US US09/993,640 patent/US6831091B2/en not_active Expired - Lifetime
-
2003
- 2003-04-14 IS IS6788A patent/IS6788A/is unknown
- 2003-04-22 BG BG107752A patent/BG107752A/bg unknown
- 2003-04-24 CR CR6963A patent/CR6963A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303341A patent/ZA200303341B/en unknown
- 2003-05-13 MA MA27158A patent/MA26960A1/fr unknown
- 2003-05-20 HR HR20030408A patent/HRP20030408A2/hr not_active Application Discontinuation
- 2003-05-27 NO NO20032388A patent/NO325187B1/no unknown
- 2003-05-28 EC EC2003004628A patent/ECSP034628A/es unknown
-
2004
- 2004-03-22 HK HK04102071A patent/HK1059085A1/xx not_active IP Right Cessation
-
2006
- 2006-11-13 CY CY20061101645T patent/CY1106240T1/el unknown
-
2007
- 2007-10-29 JP JP2007279951A patent/JP4971946B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0115621A (pt) | Sais de isotiazol-4-carboxamida e seus usos como agentes anti-hiperproliferação | |
BRPI0908353B8 (pt) | composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica | |
ES2323137T3 (es) | Composicion antiparasitaria que contiene una sal de amina organica de closantel. | |
BR0104228A (pt) | Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos | |
BRPI0017548B8 (pt) | Composto | |
BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
BR9910900A (pt) | Derivados isotiazol úteis como agentes anticancerìgenos | |
BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
UY30438A1 (es) | Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos | |
BR0312216A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto | |
BR0114323A (pt) | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto | |
BR0309553A (pt) | Composto ou sal farmaceuticamente aceitável ou éster ou amida hidrolisável in vivo deste, processo para prepará-lo, composição farmacêutica, uso do composto, e, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, e para tratar câncer em um animal de sangue quente | |
ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
BRPI0408990A (pt) | derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase | |
BRPI0416216A (pt) | composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina | |
BRPI0409986A (pt) | derivados de pirimidina fundida com atividade de crf | |
NZ542690A (en) | Muscarinic M1 receptor agonists for pain management | |
BR0308162A (pt) | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso | |
BRPI0417958A (pt) | composto, composição farmacêutica, processo para a preparação de um sal maleato, uso de um sal maleato, e, método para produzir um efeito redutor na permeabilidade antiangiogênica e/ou vascular em um animal de sangue quente | |
BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
BR9909253A (pt) | Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico | |
BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
BRPI0414780B8 (pt) | composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto | |
BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: PFIZER INC. (US) , OSI PHARMACEUTICALS, INC. (US) |